Update: A bigger, better Japanese partnership
Athersys has made progress on a number of clinical and commercial fronts in the first months of 2016. Most recently, it reported a one-year follow-up from the Phase II stroke trial, which showed that patients receiving MultiStem improved significantly more than placebo over the course of the year. Also, Athersys and Healios K.K. announced a partnership to commercialize MultiStem in Japan for ischemic stroke with the option to develop other indications. The company expects to initiate a stroke trial in Japan in H216.Athersys is a biotechnology company that is focused in the field of regenerative medicine. The company's MultiStem? cell therapy, a patented and proprietary allogeneic stem cell product, is its primary platform product and is in clinical development. The company's existing clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the existing standard of care is limited or inadequate for a number of patients. The company has a collaboration with HEALIOS K.K., to develop and commercialize MultiStem for the treatment of certain indications in Japan.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.